Xilio Therapeutics, Inc.

NasdaqGS XLO

Xilio Therapeutics, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD -0.00

Xilio Therapeutics, Inc. Dividend Per Share is USD -0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Dividend per share represents the dividends distributed per share. Indicates dividend yield potential on a per-share basis.

Xilio Therapeutics, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -0.00, a 0.00% change year over year.
Xilio Therapeutics, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -0.00, a 0.00% change year over year.
Xilio Therapeutics, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -0.00.

Key data

Date	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)	Return on Equity (ROE)

NasdaqGS: XLO

Xilio Therapeutics, Inc.

CEO	Dr. Rene Russo BCPS, Pharm.D.
IPO Date	Oct. 22, 2021
Location	United States
Headquarters	828 Winter Street
Employees	73
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Key trends

Past 5 years